Psych HealthPGx Panel
Pharmacogenomics testing for mental health
RPRD’s Psych HealthPGx Panel provides broad and actionable insights to help the clinicians make informed treatment decisions. The results of the test may help in choosing the right medications and the appropriate dose for patients undergoing treatments for certain psychiatric conditions, such as depression, anxiety, obsessive compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD). The clinical report that contains the test results also includes additional treatment information for therapeutic areas such as pain management, cancer, and cardiovascular care, strictly based on the guidelines published by Clinical Pharmacogenomics Implementation Consortium (CPIC). Our strictly evidence-based interpretations mean full transparency in how we translate the pharmacogenetic test results into clinically useful interpretations.
Evidence-based
The gene coverage of the panel has been selected and curated by RPRD’s clinicians and scientists following strong peer-reviewed scientific evidence and industry’s highest standards of actionability. The Psych HealthPGx Panel clinical report fully adheres to the recommendations by the CPIC clinical guidelines and the FDA drug labeling, with clear annotations and references.
Created for all ethnicities
The panel covers a broad array of genetic alleles/variants of the key PGx genes, including not only common, but also rare and ethnicity-specific alleles. This broad coverage is particularly important when analyzing diverse populations because overlooking these rare or ethnicity-specific alleles could miss clinically important genetic information for these patients. RPRD’s PGx testing transcends ethnic diversity and generates highly accurate testing results for every patient.
Go beyond mental illness, to care for comorbidities
The panel provides extensive insights beyond treatment regimens with psychotropic medications. It helps clinicians make comprehensive therapeutic decisions when treating patients with various comorbidities.
Gene-drug pairs
| Psychiatry Drugs | Brand names | Associated genes |
|---|---|---|
| Amitriptyline | Elavil | CYP2C19, CYP2D6 |
| Atomoxetine | Strattera | CYP2D6 |
| Citalopram | Celexa | COMT, CYP2C19, FKBP5, GRIK4, HTR2A, HTR2C, SLC6A4, TXNRD2 |
| Clomipramine | Anafranil | CYP2C19, CYP2D6 |
| Clozapine | Clozaril | ANKK1, DRD2, MC4R |
| Desipramine | Norpramin | CYP2D6 |
| Doxepin | Silenor, Zonalon, Prudoxin | CYP2C19, CYP2D6 |
| Escitalopram | Lexapro | COMT, CYP2C19, SLC6A4, TXNRD2 |
| Fluoxetine | Prozac, Sarafem | COMT, FKBP5, TXNRD2 |
| Fluvoxamine | Luvox | COMT, CYP2D6, TXNRD2 |
| Imipramine | Tofranil | CYP2C19, CYP2D6 |
| Mirtazapine | Remeron | FKBP5 |
| Nortriptyline | Pamelor | CYP2D6 |
| Olanzapine | Zyprexa | ANKK1, DRD2, HTR2C, MC4R, CYP2D6 |
| Paroxetine | Paxil | COMT, CYP2D6, FKBP5, HTR1A, TXNRD2 |
| Risperidone | Risperdal | ANKK1, DRD2, HTR2C, MC4R |
| Sertraline | Zoloft | COMT, CYP2C19, TXNRD2 |
| Trimipramine | Surmontil | CYP2C19, CYP2D6 |
| Venlafaxine | Effexor | FKBP5 |
| Other Drugs | Brand names | Associated genes |
|---|---|---|
| Clopidogrel | Plavix | CYP2C19 |
| Codeine | CYP2D6 |
|
| Dexlansoprazole | Dexilant | CYP2C19 |
| Digoxin | Lanoxin, Digox | ABCB1 |
| Esomeprazole | Nexium | CYP2C19 |
| Fentanyl | Duragesic, Sublimaze | ABCB1 |
| Hydrocodone | Zohydro ER | CYP2D6 |
| Lansoprazole | Prevacid | CYP2C19 |
| Methadone | Dolophine, Methadose | CYP2D6 |
| Methotrexate | Rheumatrex | ABCB1 |
| Omeprazole | Prilosec | CYP2C19 |
| Ondansetron | Zofran | ABCB1 |
| Oxycodone | Oxycontin, Roxicodone | CYP2D6 |
| Pantoprazole | Protonix | CYP2C19 |
| Rabeprazole | Aciphex | CYP2C19 |
| Tropisetron | Navoban | CYP2D6 |
| Voriconazole | Vfend | CYP2C19 |
| Nevirapine | Viramune | ABCB1 |
| Simvastatin | Zocor | ABCB1 |
| Tamoxifen | Soltamox | CYP2D6 |
| Tramadol | Ultram, Conzip | CYP2D6 |
Alleles tested
| Genes | Alleles |
|---|---|
| ABCB1 | ABCB1_c.1795G>A(A599T) (rs2235036); ABCB1_c.239C>A(A80E) (rs9282565); ABCB1_c.2677G>T/A(A893S/T) (rs2032582); ABCB1_c.2995G>A(A999T) (rs72552784); ABCB1_c.1696G>A(E566K) (rs28381902); ABCB1_c.49T>C(F17L) (rs28381804); ABCB1_c.3188G>C(G1063A) (rs2707944); ABCB1_c.554G>T(G185V) (rs1128501); ABCB1_c.2485A>G(I829V) (rs2032581); ABCB1_c.2506A>G(I836V) (rs28381967); ABCB1_c.61A>G(N21D) (rs9282564); ABCB1_c.131A>G(N44S) (rs1202183); ABCB1_c.3151C>G(P1051A) (rs28401798); ABCB1_c.3320A>C(Q1107P) (rs55852620); ABCB1_c.1777C>T(R593C) (rs28381914); ABCB1_c.3421T>A(S1141T) (rs2229107); ABCB1_c.1199G>A(S400N) (rs2229109); ABCB1_c.3751G>A(V1251I) (rs28364274); ABCB1_c.2401G>A(V801M) (rs2235039) |
| ANKK1 | ANKK1_c.453A>C (rs4938013); rs7118900; rs1800497 |
| DRD2 | rs1125394; rs1124493; rs6275; rs1801028; rs2283265; rs2440390; rs4648317; rs2734841; rs1076560; rs1110976; rs1079598; rs6277; rs6279; rs4436578; DRD2_c.-32+24002G>A (rs4460839); rs6279 DRD2_c.285+2169C>T (rs2734833) |
| FKBP5 | rs3800373; rs9380524; rs1360780; rs4713916 |
| GRIK4 | GRIK4_c.2267-1150G>A (rs12800734); rs1954787 |
| HTR1A | rs10040843; rs6875401; rs6295 rs1364043; rs114058084; rs10042486; chr5:63121377 |
| HTR2A | rs9316233; rs7997012; rs6318; rs6314; rs6313; rs6311; rs518147; rs3813929; rs3813928; rs2497538; rs1414334; HTR2A_c.614-25509C>T (rs659734); HTR2A_c.613+8832A>G (rs17288723); HTR2A_c.516C>T(p.=) (rs6305); HTR2A_c.-344G>A (rs6312) |
| HTR2C | rs3813929; rs2497538; HTR2C_c.-238+2217N>T (rs539748); rs3813928; rs518147; rs6318; rs1414334 |
| MC4R | rs11872992 |
| TXNRD2 | rs13306278; rs9606186; rs2020917 |
| SLC6A4 | SLC6A4_L/S allele (rs774676466); rs2531 |
| COMT | COMT_c.1-98A>G(SolublePromoter); COMT_c.186C>T(H62=); COMT_c.408C>G(L136=); COMT_c.472G>A(V158M); COMT_c.214G>T(A72S); COMT_c.304G>A(A102T) |
| CYP2C19 | *1; *2; *3; *4A; *4B; *5; *6; *7; *8; *9; *10; *12; *13; *14; *15; *16; *17; *18; *19; *22; *23; *24; *25; *26; *28; *34; *35; CYP2C19_12834G>C(A161P) (rs181297724) CYP2C19_80248G>A(D360N) (rs144036596) CYP2C19_19194_19195insG(E241Frameshift) (rs72558185) CYP2C19_12460G>C(E92D) (rs17878459) CYP2C19_17814T>C(F168L) (rs28399510) CYP2C19_90052delG(G439Frameshift) CYP2C19_12405T>C(M74T) (rs28399505) CYP2C19_57876C>G(T302R) (rs58259047) CYP2C19_12690G>A(V113I) (rs145119820) CYP2C19_80161G>A(V331I) (rs3758581) CYP2C19_87242G>A(V394M) (rs55948420) |
| CYP2D6 | *1; *2; *3A; *3B; *4; *5; *6; *7; *8; *9; *10; *11; *12; *14; *15; *17; *18; *19; *20; *22; *23; *25; *28; *29; *31; *33; *35; *37; *38; *40; *41; *42; *43; *44; *45; *46; *47; *48; *49; *51; *53; *54; *55; *56A; *56B; *59; *62; *70; *71; *72; *73; *75; *81; *82; *84; *85; *86; *88; *89; *95; *100; *101; *102; *103; *107; *109; *114; CYP2D6_974C>A(L91M) (rs28371703) CYP2D6_984A>G(H94R) (rs28371704) CYP2D6_1858C>T(R173C) (rs67780109) CYP2D6_1976G>A(G212E) (rs5030866) CYP2D6_2616_2617delA(K281Frameshift) (rs28371720) CYP2D6_2938C>T(P325L) (rs140513104) CYP2D6_3265G>A(R365H) (rs1058172) CYP2D6*52_3877G>A(E418K) (rs28371733) CYP2D6_3887T>C(L421P) (rs72549345) CYP2D6_4123C>T(S467L) (rs370012110) CYP2D6_4131A>G(T470A) (rs1135835) CYP2D6_4155C>T(H478Y) (rs28371735) CYP2D6_4180G>C(S486T) (rs1135840) CYP2D6_4192A>G(Y490C) (rs199722016) |
How it works?
We accept whole blood, saliva or buccal swab samples. As a healthcare provider, you can choose to collect the patient’s blood sample or have the patient collect a salvia or buccal swab sample at home with our in-home collection kit. Depending on what option you choose, we offer to send the saliva or buccal swab collection kits either directly to your office or to the patient’s home, free of charge.
Please contact us to set up the process.
Only a fully licensed healthcare provider treating the patient can order the test.
Please download and fill out the Test Requisition Form. Please send the completed TRF together with the patient’s whole blood sample to us or send us the TRF only and we will arrange the sample in-home collection directly with the patient.
RPRD’s pharmacogenomics testing is performed in our fully CLIA-certified clinical grade genetic testing lab.
If it is the first time you send us the patient’s sample, please contact us to establish the process.
RPRD provides three payment options: institutional billing, patient self-pay and insurance billing. Please contact us if you would like to learn more about each of the payment options.
Ready to talk?
If you are ready to get started or still have questions, we are here to help you. Call us at (414)-316-3097 or email info@rprdx.com.
FAQ
All our tests for clinical decision-making should be ordered by a licensed healthcare provider or a genetic counselor. Pharmacists also play a critical role in integrating PGx into patient care. In the United States, in general, pharmacists need collaborative practice agreements in place to order the test. However, certain states may have specific state laws regulating pharmacists’ ability to order and interpret lab results.
If the specimen meets our quality requirements, typical turnaround time for the test is 2 weeks.
Institutional Billing Info
Patient’s self-pay option
For the Psych HealthPGx Panel, we also offer patient self-pay option. Please contact us for more details.
Insurance Billing
Patient’s out-of-pocket cost may vary depending on the patient’s health insurance plan. RPRD will contact the patient’s insurance provider to understand the potential total out-of-pocket cost (estimated only). We promise to process the test only if the patient is comfortable with the cost. RPRD also offers Financial Assistance Program to eligible patients to help reduce the out-of-pocket costs.
If you have any questions about your patient’s test results or need any help to understand the report, our board-certified medical geneticist and experienced PGx scientists are available to guide you through the test results and answer any questions.
We do not offer consultation to the patients directly.
Test menu
At RPRD, we offer a wide range of PGx testing service.
Lab accreditation
All samples are processed in our CLIA-certified diagnostic laboratory with robust quality assurance programs that surpass required diagnostic testing standards.